4//SEC Filing
Graf James A 4
Accession 0001213900-24-112773
CIK 0001845459other
Filed
Dec 25, 7:00 PM ET
Accepted
Dec 26, 7:20 PM ET
Size
12.7 KB
Accession
0001213900-24-112773
Insider Transaction Report
Form 4
Graf James A
Chief Executive Officer10% Owner
Transactions
- Disposition to Issuer
Private Placement Warrants
2024-12-20−757,942→ 1,145,831 totalExercise: $11.50From: 2023-10-29Exp: 2028-09-29→ Common Stock (757,942 underlying) - Other
Common Stock
2024-12-20−63,634→ 2,082,507 total - Disposition to Issuer
Working Capital Warrants
2024-12-20−93,334→ 96,472 totalExercise: $11.50From: 2023-10-29Exp: 2028-09-29→ Common Stock (93,334 underlying)
Graf Acquisition Partners IV LLC
Chief Executive Officer10% Owner
Transactions
- Disposition to Issuer
Working Capital Warrants
2024-12-20−93,334→ 96,472 totalExercise: $11.50From: 2023-10-29Exp: 2028-09-29→ Common Stock (93,334 underlying) - Other
Common Stock
2024-12-20−63,634→ 2,082,507 total - Disposition to Issuer
Private Placement Warrants
2024-12-20−757,942→ 1,145,831 totalExercise: $11.50From: 2023-10-29Exp: 2028-09-29→ Common Stock (757,942 underlying)
Footnotes (4)
- [F1]On December 20, 2024, Graf Acquisition Partners IV LLC (the "Sponsor") distributed 63, 634 shares of common stock of the NKGen Biotech, Inc. (f/k/a Graf Acquisition Corp. IV, the "Issuer") to Christine Low, Franklin FTX I, L.P., and Andrew Bail, each a member of the Sponsor and initially entitled to the distribution of 15% of the original shares of common stock held by the Sponsor, which were issued upon the conversion of the shares of Class B common stock of Graf Acquisition Corp. IV, upon September 29, 2024, the one-year anniversary of the closing of the business combination between Graf Acquisition Corp. IV and the Issuer, and the additional parties thereto.
- [F2]The Sponsor is the record holder of the securities reported herein. James A. Graf is the managing member of the Sponsor. Mr. Graf has voting and investment discretion with respect to the securities held of record by the Sponsor.
- [F3]The Private Placement Warrants were distributed by the Sponsor to its members in accordance with its limited liability company agreement, as amended. The Private Placement Warrants were initially purchased at a price of $1.50 per Private Placement Warrant in accordance with the private placement warrant agreement between the Sponsor and the Issuer.
- [F4]The Working Capital Warrants were distributed by the Sponsor to its members in accordance with its limited liability company agreement, as amended. The Working Capital Warrants were issued in connection with the conversion of working capital loans, entered into between the Sponsor and the Issuer, at a price of $1.50 per Working Capital Warrant.
Documents
Issuer
NKGen Biotech, Inc.
CIK 0001845459
Entity typeother
Related Parties
1- filerCIK 0001519672
Filing Metadata
- Form type
- 4
- Filed
- Dec 25, 7:00 PM ET
- Accepted
- Dec 26, 7:20 PM ET
- Size
- 12.7 KB